Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 in Advanced Hypertensive LVH and HFpEF
NCT03928158Phase 2Completed
- Start
- May 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), left ventricular hypertrophy (LVH). Started May 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT03928158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928158.